Emerald Mutual Fund Advisers Trust’s Madrigal Pharmaceuticals MDGL Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.64M	Sell	16,500 -8,496	-34%	-$4.06M	0.42%	90
2025 Q4	$14.6M	Sell	24,996 -10,095	-29%	-$5.16M	0.71%	62
2025 Q3	$16.1M	Sell	35,091 -1,829	-5%	-$682K	0.83%	46
2025 Q2	$11.2M	Buy	36,920 +1,682	+5%	+$501K	0.68%	54
2025 Q1	$11.7M	Buy	35,238 +16,582	+89%	+$5.45M	0.83%	46
2024 Q4	$5.76M	Sell	18,656 -3,031	-14%	-$853K	0.35%	86
2024 Q3	$4.6M	Sell	21,687 -54,072	-71%	-$13.8M	0.24%	106
2024 Q2	$21.2M	Hold	75,759	–	–	1.11%	35
2024 Q1	$20.2M	Buy	75,759 +36,479	+93%	+$8.6M	1.05%	34
2023 Q4	$9.09M	Buy	+39,280	New	+$6.87M	0.48%	83
2023 Q3	–	Sell	-50,073	Closed	-$11.6M	–	246
2023 Q2	$11.6M	Sell	50,073 -16,125	-24%	-$4.37M	0.63%	75
2023 Q1	$16M	Buy	66,198 +55,729	+532%	+$15.2M	0.95%	40
2022 Q4	$3.04M	Buy	+10,469	New	+$1.02M	0.19%	115

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's MDGL Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its Madrigal Pharmaceuticals (MDGL) stake by 34% in Q1 2026, selling an estimated $4.06M and leaving 16,500 shares worth $8.64M. The position accounts for 0.42% of the portfolio, ranked #90.

Emerald Mutual Fund Advisers Trust first reported a position in MDGL in Q4 2022 and has held it in 13 quarters since. The position peaked at $21.2M in Q2 2024. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Emerald Mutual Fund Advisers Trust held 16,500 shares of Madrigal Pharmaceuticals worth $8.64M as of Q1 2026.
Emerald Mutual Fund Advisers Trust sold 8,496 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $4.06M.
Madrigal Pharmaceuticals made up 0.42% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #90 holding.
Emerald Mutual Fund Advisers Trust first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
Emerald Mutual Fund Advisers Trust's Madrigal Pharmaceuticals position peaked at $21.2M in Q2 2024.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.